Skip to main content

Table 7 Estimates of clinical impact

From: An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

  Affected patellar reflex Respiratory depression Skipped or delayed dose Calcium gluconate use
Incidence amongst 9556 women 1.6% 1.3% 3.6% 0.18%
Number of pre-eclamptic/eclamptic women needed to treat to experience one incidence (i.e., number needed to harm) 61 77 27 555
Scenario: A hospital delivers 5000 women annually. Assuming a rate of PE/E of 5%, 250 women annually will require treatment with magnesium sulfate.
Frequency of 1 case (months) 2.9 months 3.7 months 1.3 months 26.7 months